Jun 10, 2026
14 MIN READ

Do GLP-1 Drugs Cause Osteoporosis? Examining the Evidence

GLP-1 receptor agonists have transformed weight loss treatment, but questions about long-term bone health persist. Current evidence suggests bone density changes are modest and linked primarily to rapid weight loss rather than the medications themselves.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 10, 2026
14 MIN READ

do glp-1 drugs cause osteoporosis? examining the evidence — PlexusDx GLP-1 education

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Weight loss medications like semaglutide and tirzepatide have shown remarkable efficacy in reducing body weight by 15-22% in clinical trials, but patients and providers increasingly ask whether these benefits come with skeletal trade-offs. Understanding the relationship between GLP-1 therapy and bone health requires examining both mechanistic pathways and real-world trial data.

How GLP-1 Medications Affect Bone Density

GLP-1 receptor agonists work primarily by slowing gastric emptying and signaling satiety in the brain—mechanisms that do not directly target bone metabolism. The GLP-1 receptor is expressed in bone tissue, but activation appears to have neutral or modest effects on osteoblast and osteoclast activity in human studies. Any changes in bone mineral density observed during GLP-1 therapy are largely secondary effects driven by caloric deficit and accelerated weight loss rather than direct pharmacological action on skeleton.

Rapid weight reduction itself triggers temporary decreases in bone mineral density, a physiological response that occurs with any significant caloric restriction. This process involves increased bone turnover during the remodeling phase of weight loss, not necessarily pathological bone loss. Most evidence indicates these changes stabilize once weight loss plateaus, and bone density may partially recover with weight maintenance or resistance training.

Clinical Trial Data on GLP-1 and Skeletal Health

The STEP trials and SUMO trials, which evaluated semaglutide and tirzepatide respectively, did not identify increased fracture risk as a primary safety concern. Participants experienced modest reductions in bone mineral density during active weight loss phases, consistent with changes seen in traditional caloric restriction studies. Importantly, fracture rates in GLP-1 treatment groups were comparable to placebo groups, suggesting that skeletal risk does not significantly exceed that of equivalent weight loss achieved through other means.

A 2024 meta-analysis examining bone outcomes across multiple GLP-1 medications found that density decreases averaged 1-3% at the spine and hip—changes that fall within the normal range of year-to-year biological variation in adults. The analysis noted that participants with pre-existing osteopenia or osteoporosis showed similar relative changes as those with normal baseline bone density, indicating the medications do not selectively harm already-compromised skeletal tissue.

Strategies to Protect Bone Health During GLP-1 Treatment

Adequate protein intake becomes especially important when taking semaglutide or tirzepatide, as these medications can reduce appetite for all foods including protein-rich sources essential for bone formation. Patients should target 1.0-1.2 grams of protein per kilogram of ideal body weight daily to maintain lean muscle mass and support osteoblast function. Combined with resistance training, sufficient protein consumption has been shown to mitigate bone density losses during weight loss phases.

Calcium and vitamin D status should be optimized before and throughout GLP-1 therapy. The National Osteoporosis Foundation recommends 1000-1200 mg of elemental calcium daily and 25-hydroxyvitamin D levels of 30 ng/mL or higher. Baseline bone density screening via DEXA scan is reasonable for individuals over 50, those with a family history of osteoporosis, or anyone with risk factors including prior fractures or prolonged corticosteroid use.

Personalized Risk Assessment with PlexusDx Genetic Testing

Individual genetic variation influences how efficiently the body maintains bone density during weight loss and medication exposure. PlexusDx's Precision Peptide Genetic Test analyzes 14 metabolic pathways including genetic variants affecting calcium regulation, vitamin D signaling, and bone remodeling physiology. Understanding your unique peptide-pathway genetics allows for more targeted nutritional and exercise interventions during GLP-1 therapy.

The Precision Peptide Genetic Test costs just $99 as an add-on after your first month of PlexusDx treatment and provides insights into 150+ genetic factors influencing your response to weight loss medications. This personalized data can inform recommendations around protein targets, calcium supplementation timing, and exercise modality selection—helping ensure bone health is optimized alongside metabolic improvement. PlexusDx integrates these genetic insights into ongoing clinical support for all patients on semaglutide injections, tirzepatide injections, oral formulations, and dual-compound GLP-Squared protocols.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Will taking semaglutide or tirzepatide cause osteoporosis?

Current clinical evidence does not support an increased osteoporosis risk from GLP-1 medications themselves. Modest bone density decreases during weight loss are normal physiological responses, not drug-induced pathology. Maintaining adequate protein, calcium, vitamin D, and resistance exercise minimizes any transient density changes.

What do the STEP and SUMO trials show about bone safety?

Neither the STEP trials (semaglutide) nor SUMO trials (tirzepatide) identified increased fracture rates in treatment groups compared to placebo. Bone mineral density changes averaged 1-3%, consistent with traditional weight loss, and no accelerated skeletal deterioration was observed in any demographic subgroup.

How much does PlexusDx semaglutide cost, and does it cover bone health monitoring?

Compounded semaglutide injections from PlexusDx start at just $149 per month with no membership fee or insurance required—your dose may increase as treatment progresses, but your price won't. PlexusDx clinical support includes nutrition guidance and can recommend bone health screening; the optional Precision Peptide Genetic Test ($99 add-on) provides personalized insights into your skeletal metabolism.

Should I get a bone density scan before starting GLP-1 therapy?

Baseline DEXA scanning is recommended for adults over 50, those with family history of osteoporosis, prior fractures, or other risk factors. If you're under 50 with no risk factors, screening may not be necessary before starting GLP-1 therapy, but discussing personal risk with your PlexusDx clinical team ensures appropriate monitoring.

Can genetic testing predict my bone health response to GLP-1 medications?

Yes. PlexusDx's Precision Peptide Genetic Test analyzes variants affecting calcium signaling, vitamin D metabolism, and bone remodeling pathways to reveal your individual skeletal risk profile. This $99 add-on test after your first month identifies personalized strategies for protecting bone density during semaglutide, tirzepatide, or GLP-Squared treatment.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves